Amgen Inc., of Thousand Oaks, Calif., and Allergan plc, of Dublin, said the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the marketing authorization of ABP-215, a biosimilar to Avastin (bevacizumab, Roche Holding AG).